Ultragenyx Pharmaceutical (RARE) Gains from Sales and Divestitures (2015 - 2016)
Ultragenyx Pharmaceutical (RARE) reported Gains from Sales and Divestitures of $52273.0 for Q4 2016, up 187.07% year-over-year from $18209.0 in Q1 2016, and up 187.07% quarter-over-quarter from $18209.0 in Q4 2015.
Ultragenyx Pharmaceutical (RARE) Gains from Sales and Divestitures (2015 - 2016) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 2 years of Gains from Sales and Divestitures data on file, last reported at $52273.0 in Q4 2016.
- Gains from Sales and Divestitures for Q4 2016 came in at $52273.0, up 187.07% year-over-year; the trailing twelve-month figure through Dec 2016 was $52273.0 (up 187.07% YoY), and the FY2016 annual result was $52273.0, up 187.07% from the prior year.
- Gains from Sales and Divestitures grew to $52273.0 in Q4 2016 per RARE's latest filing, from $18209.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $52273.0 in Q4 2016 and troughed at $18209.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 52,273.00 |
| Dec 31, 2016 | 52,273.00 |
| Dec 31, 2015 | 18,209.00 |
| Dec 31, 2015 | 18,209.00 |